Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Main characteristics of the eligible studies from systematic review

From: Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study

First author Country Stage Age Abs Cut off scores (IHC) Cancer Poor Moderate/well Stage 3–4 Stage 1–2 Node + Node _ Serous Non-serous Survival rate Clinical outcomes
N (E+ %) E+/N E+/N E+/N E+/N E+/N E+/N E+/N E+/N
Hamanishi 2007 [12] Japan 1–4 55 Clone 27A2 Scores 2 and 3 70 (68.6%)    29/39 19/31 11/14 37/56 21/28 27/42 5-year OS, PFS
Darb-Esfahani 2016 [28] Germany 1–4 60 Clone EPR1161 IRS 1–12 215 (93.9%)          5-year OS, PFS
Webb 2016 [27] Canada 1–3 NA Cone SP142 1% 490 (34.9%) 108/278 63/212 37/83 134/407    112/206 59/284 10-year DSS
Li 2017 [21] China 1–4 NA Ventana Scores 3–6 140 (25%)          5-year PFS
Mesnage 2017 [26] France 2–4 NA Clone E1L3N 5% 50 (30%)    14/49 1/1       
Chatterjee 2017 [25] UK NA NA Dako Median 48 (NA)          5-year PFS
Li 2017 [21] China 1–4 NA SP263 Scores 2 and 3 209 (15.8%)    15/128 18/81    13/113 20/95 5-year OS
Wang 2017 [23] China 1–4 57 Clone E1L3N 5% 107 (24.3%)    24/81 2/26      5-year OS
Zhu 2017 [22] China 1–4 53 ab205921 10% 122 (44.3%)    27/47 27/75      5-year OS, PFS
Mills 2018 [13] USA 1–4 NA Clone SP142 1% 112 (28.6%)    26/92 6/19      3-year OS
Drakes 2018 [20] USA 1–4 61 ab205921 Scores 2–4 55 (32.7%) 17/41 1/13 13/46 5/9       
Zhu 2018 [19] China 1–4 53 Clone SP142 10% 112 (58.9%) 10/16 46/80 41/70 25/42 20/31 37/63 45/75 21/37 5-year DFS, OS
  1. IHC immunohistochemistry, NA not applicable, Ab antibody, E+ positive expression, N the number of the study population, IRS immuno-reactivity score, OS overall survival, DS disease-specific survival, DFS disease-free survival, PFS progression-free survival